Companies: 10,795·Total market cap: $144.5T
G1 Therapeutics, Inc.

G1 Therapeutics, Inc.

GTHXNASDAQHealthcare
$7.16
+$0.01(+0.14%)
Market Cap$377748712
P/E Ratio—
52W High$7.19
52W Low$1.08
SEC Filings

G1 Therapeutics, Inc. (GTHX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001560241 · GTHX · NASDAQ · as of Jun 9, 2026

Filing snapshot

562
Total Filings
SC 13G/A
Latest Form
2024-11-13
Most Recent
2017
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001560241 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2024-02-28
Fiscal Year End
Feb 28, 2024
Accession No.
0001628280-24-007601
Primary Document
gthx-20231231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001560241 · Accession 0001628280-24-007601

Latest Key Filings

10-QQuarterly Report
10-Q
2024-08-08
View 10-Q on SEC
8-KCurrent Report
8-K
2024-09-18Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2024-11-13
View
15-12G15-12G
15-12G
2024-09-30
View
S-8 POSS-8 POS
S-8 POS
2024-09-18
View
S-8 POSS-8 POS
S-8 POS
2024-09-18
View
S-8 POSS-8 POS
S-8 POS
2024-09-18
View
S-8 POSS-8 POS
S-8 POS
2024-09-18
View
S-8 POSS-8 POS
S-8 POS
2024-09-18
View
S-8 POSS-8 POS
S-8 POS
2024-09-18
View
S-8 POSS-8 POS
S-8 POS
2024-09-18
View
25-NSE25-NSE
25-NSE
2024-09-18
View
8-KCurrent Report
8-K
2024-09-18
View
SC 14D9/ASC 14D9/A
SC 14D9/A
2024-09-18
View
SC TO-T/ASC TO-T/A
SC TO-T/A
2024-09-18
View
SC 14D9/ASC 14D9/A
SC 14D9/A
2024-09-10
View
SC 14D9/ASC 14D9/A
SC 14D9/A
2024-09-05
View
Showing 1–15 of 277 filingsForm 4 / 144 hidden· 562 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001560241  |  Exchange: NASDAQ · Healthcare

G1 Therapeutics, Inc. (NASDAQ: GTHX) has submitted 562 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2017. As a Healthcare sector company with CIK 0001560241, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is G1 Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent G1 Therapeutics, Inc. 10-K was filed on 2024-02-28 for fiscal year ending 2024. Historical GTHX 10-K annual reports are available from 2012 through 2024.

Investors researching G1 Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
CLYM SEC Filings →CTEV SEC Filings →ITOS SEC Filings →SLGC SEC Filings →YMAB SEC Filings →RVNC SEC Filings →ORTX SEC Filings →VIGL SEC Filings →
→ GTHX Financials→ GTHX Earnings→ GTHX Insider Trades

Frequently Asked Questions

GTHX SEC Filings · 8 questions

G1 Therapeutics, Inc. (GTHX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 562 filings and access original documents at no cost. G1 Therapeutics, Inc.'s CIK is 0001560241.

GTHX SEC filingsG1 Therapeutics, Inc. SEC documentsfind GTHX 10-K